Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough blood cancers: ARD103 trial opens

NCT ID NCT06680752

Recruiting now Disease control Sponsor: ARCE Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called ARD103 in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or not responded to standard treatments. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink or control the cancer. About 49 participants will receive the drug at multiple hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, IN RELAPSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome myelodysplastic syndrome with excess blasts

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA, IN RELAPSE ACUTE MYELOID LEUKEMIA, REFRACTORY MDS (MYELODYSPLASTIC SYNDROME)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Novant Health Cancer Institute

    RECRUITING

    Charlotte, North Carolina, 28204, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Novant Health Cancer Institute

    RECRUITING

    Winston-Salem, North Carolina, 27201, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.